Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
new york blog main
new york top stories
4
×
alnylam pharmaceuticals
boston
boston top stories
drugs
akcea therapeutics
biotech
clinical trials
fda
hereditary transthyretin amyloidosis
inotersen
national top stories
patisiran
regeneron pharmaceuticals
rna interference
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
tafamidis
alirocumab
amgen
barry greene
biontech
boehringer ingelheim
boston university
curevac
dan ollendorf
deals
eli lilly
european medicines agency
evercore isi
evolocumab
harvard pilgrim health care
heart attack
inclisiran
What
rna
4
×
alnylam
drug
evidence
fda
medicine
medicines
new
time
uses
ago
approve
approves
awaits
based
bets
bio
biological
cancer
cells
cholesterol
comes
companies
crossed
cut
data
date
deal
decades
decision
discovered
effective
ema
employ
enticed
europe
fingers
follows
friday
gene
Language
Current search:
rna
×
" new york top stories "
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines
